Great West Life Assurance Co. Can cut its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 16.6% in the first quarter, HoldingsChannel.com reports. The fund owned 10,930 shares of the company’s stock after selling 2,170 shares during the period. Great West Life Assurance Co. Can’s holdings in LivaNova were worth $1,060,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of LIVN. Norges Bank bought a new position in shares of LivaNova during the fourth quarter valued at $46,478,000. JPMorgan Chase & Co. lifted its holdings in shares of LivaNova by 31.5% during the first quarter. JPMorgan Chase & Co. now owns 647,760 shares of the company’s stock valued at $62,995,000 after acquiring an additional 155,079 shares during the period. Gotham Asset Management LLC bought a new position in shares of LivaNova during the fourth quarter valued at $13,750,000. BlackRock Inc. lifted its holdings in shares of LivaNova by 2.2% during the fourth quarter. BlackRock Inc. now owns 5,915,599 shares of the company’s stock valued at $541,101,000 after acquiring an additional 127,669 shares during the period. Finally, Rhenman & Partners Asset Management AB lifted its holdings in shares of LivaNova by 99.5% during the first quarter. Rhenman & Partners Asset Management AB now owns 240,600 shares of the company’s stock valued at $23,398,000 after acquiring an additional 120,000 shares during the period. 84.40% of the stock is owned by institutional investors.
Shares of NASDAQ:LIVN opened at $72.39 on Friday. LivaNova PLC has a twelve month low of $64.80 and a twelve month high of $131.54. The firm has a market capitalization of $3.60 billion, a PE ratio of 22.84, a price-to-earnings-growth ratio of 3.14 and a beta of 0.61. The company has a debt-to-equity ratio of 0.13, a current ratio of 0.87 and a quick ratio of 0.61.
LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, May 1st. The company reported $0.54 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.11. LivaNova had a positive return on equity of 9.38% and a negative net margin of 19.64%. The company had revenue of $250.80 million during the quarter, compared to analyst estimates of $254.89 million. During the same period last year, the company posted $0.68 earnings per share. The firm’s quarterly revenue was up .2% compared to the same quarter last year. Equities analysts anticipate that LivaNova PLC will post 2.6 earnings per share for the current year.
A number of brokerages have recently weighed in on LIVN. BTIG Research restated a “hold” rating on shares of LivaNova in a research note on Tuesday, March 5th. BidaskClub upgraded LivaNova from a “hold” rating to a “buy” rating in a research note on Wednesday, March 27th. Needham & Company LLC restated a “buy” rating and issued a $120.00 target price (down from $135.00) on shares of LivaNova in a research note on Wednesday, February 27th. ValuEngine lowered LivaNova from a “buy” rating to a “hold” rating in a research note on Friday, April 5th. Finally, Piper Jaffray Companies lowered their target price on LivaNova from $120.00 to $90.00 and set an “in-line” rating for the company in a research note on Wednesday, May 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $106.40.
In other LivaNova news, Director William A. Kozy bought 1,000 shares of the stock in a transaction dated Thursday, May 2nd. The stock was bought at an average cost of $72.81 per share, for a total transaction of $72,810.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Alfred J. Novak sold 1,300 shares of the firm’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $70.63, for a total value of $91,819.00. The disclosure for this sale can be found here. Company insiders own 0.41% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Great West Life Assurance Co. Can Trims Position in LivaNova PLC (NASDAQ:LIVN)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2019/06/14/great-west-life-assurance-co-can-trims-position-in-livanova-plc-nasdaqlivn.html.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
See Also: Trade War
Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN).
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.